CRISPR Therapeutics AG

CRISPR Therapeutics AG is a gene-editing biopharmaceutical company built around CRISPR/Cas9 technology and the development of gene-based medicines for serious diseases. Its most important commercial milestone is CASGEVY, the first approved CRISPR-based therapy, which it co-develops and co-commercializes with Vertex Pharmaceuticals for sickle cell disease and transfusion-dependent beta thalassemia. Beyond hemoglobinopathies, the company is building a pipeline across in vivo editing, CAR T approaches, regenerative medicine, and type 1 diabetes. The business is still heavily research- and development-driven, with value creation tied to clinical progress, regulatory approvals, manufacturing execution, and partner-led commercialization.

−18 378,7 %

−16 569,8 %

−90,6 %

13.32

13.32

— CRISPR Therapeutics AG
%
Commercial gene-edited therapy45% Approved CRISPR-based medicine and related commercialization activities for hemoglobinopathies.
Clinical-stage in vivo programs20% Programs that deliver CRISPR-based therapeutics directly into the body for liver and other targets.
Cell therapy and CAR T programs15% Engineered cell therapy candidates developed using CRISPR editing and partner collaborations.
Early-stage research platforms10% CRISPR-X and other next-generation editing technologies designed to expand the platform.
Partnership and collaboration revenue10% Milestones, option fees, and shared development economics from strategic alliances such as Vertex.

The company’s direct commercial customers are patients with severe genetic diseases, but the purchasing and...

  • Patients with hemoglobinopathiesprimary

    Patients with severe sickle cell disease or transfusion-dependent beta thalassemia who are eligible for CASGEVY through specialized treatment centers.

  • Specialty treatment centers and hospitalsprimary

    Centers that perform patient identification, cell collection, conditioning, infusion, and follow-up for approved and clinical-stage cell therapies.

  • Payers and public health systemsprimary

    Insurers and government health systems that approve and reimburse expensive one-time gene therapies based on clinical and economic evidence.

  • Strategic pharmaceutical partnersprimary

    Partners such as Vertex that co-develop, co-commercialize, manufacture, or fund programs to accelerate development and market access.

  • Clinical trial participantssecondary

    Patients enrolled in early- and mid-stage studies for in vivo, CAR T, regenerative medicine, and diabetes programs.

The company is headquartered in the United States but operates as a global gene-therapy developer with clinical,...

  • •Headquartered in the United States, with U.S. commercialization and clinical development as a core base
  • •CASGEVY is approved in the United States and other countries, creating multi-market launch exposure
  • •Europe is important because gene-therapy regulation and reimbursement differ by country
  • •China is a competitive hotspot for genetic medicine development and a source of emerging rivals
  • •Global treatment-center expansion matters because cell therapies require specialized infrastructure
  • •Manufacturing and supply-chain execution are critical across jurisdictions for patient access

The company’s strategy is to convert CRISPR/Cas9 from a platform into a portfolio of approved and clinically...

01
Commercialize and expand CASGEVYshort-term

The approved product is the clearest path to near-term value creation and validates the platform.

02
Advance in vivo editing programsmedium-term

In vivo delivery could open larger markets than ex vivo cell therapy and reduce treatment complexity.

03
Build next-generation editing and delivery platformsmedium-term

New editing chemistries and delivery methods are needed to stay competitive as the field evolves.

04
Leverage partnerships to broaden the pipelineshort-term

Collaborations reduce capital intensity and provide access to disease expertise and commercialization capabilities.

The company faces substantial clinical, regulatory, and manufacturing risk because its business depends on proving that...

high

Clinical development failure or delay

The pipeline depends on successful preclinical and clinical outcomes, and setbacks can stop or postpone commercialization.

Scope
All pipeline programs
Materiality
high
high

Manufacturing quality and supply-chain disruption

Cell and gene therapies require tightly controlled manufacturing; deviations can cause lot failures, recalls, and trial delays.

Scope
CASGEVY and future cell therapies
Materiality
high
high

Partner dependence on Vertex

Vertex is the manufacturer and exclusive license holder of CASGEVY and has significant control over the program.

Scope
CASGEVY commercialization
Materiality
high
medium

Competitive displacement by alternative editing technologies

Base editing, RNA editing, TALENs, and other platforms may prove more attractive in certain indications.

Scope
Platform and pipeline
Materiality
high
medium

Regulatory tightening for gene therapy

FDA, EMA, and MHRA scrutiny can delay or prevent approvals and increase development burden.

Scope
Global development and commercialization
Materiality
medium
ASC 606 collaboration revenue
Can cause significant quarterly volatility in reported revenue
R&D accrual estimates
Affects operating expenses and loss volatility
Co-development economics with Vertex
Can materially affect revenue mix and margin interpretation
Fair value of marketable securities
Affects other income and liquidity presentation

VERTEX PHARMACEUTICALS INC / MA

VRTX · Pharmaceutical Preparations

Caribou Biosciences, Inc.

CRBU · Biological Products, (No Diagnostic Substances)

Metagenomi Therapeutics, Inc.

MGX · Biological Products, (No Diagnostic Substances)

Vera Therapeutics, Inc.

VERA · Pharmaceutical Preparations

Beam Therapeutics Inc.

BEAM · Biological Products, (No Diagnostic Substances)

CRESCENT BIOPHARMA, INC.

CBIO · Pharmaceutical Preparations

: 11/08/2026